liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
Umeå University, Sweden.
Karolinska University Hospital, Sweden; Karolinska Institute, Sweden.
University of Uppsala Hospital, Sweden; University of Uppsala Hospital, Sweden.
Regional Cancer Centre, Sweden.
Show others and affiliations
2015 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 169, no 5, 683-688 p.Article in journal (Refereed) Published
Abstract [en]

Given that tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with chronic myeloid leukaemia (CML), we were interested in examining the possible risk of long-term adverse events, such as the emergence of other neoplasms. Therefore, we studied the development of second malignancies in 868 patients diagnosed with CML between 2002 and 2011 using the Swedish CML register, cross-linked to the Swedish Cancer register. With a median follow-up of 37 (range 0-99)years, 65 (75%) patients developed 75 second malignancies (non-haematological), 52 of which were of the invasive type. Compared to expected rates in the background population, the risk of second malignancies was higher in the CML cohort, with a standardized incidence ratio (SIR) of 152 (95% CI 113-199). The SIR before and after the second year following diagnosis of CML was 158 and 147, respectively. Among specific cancer types, gastrointestinal and nose and throat cancer were significantly increased. Founded on a population-based material, our results indicate that CML patients treated in the TKI era are at an increased risk of developing a second malignancy, with indications that this risk may more likely be linked to CML itself rather than to the TKI treatment.

Place, publisher, year, edition, pages
Wiley , 2015. Vol. 169, no 5, 683-688 p.
Keyword [en]
chronic myeloid leukaemia; treatment; malignancy
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-119236DOI: 10.1111/bjh.13346ISI: 000354489800009PubMedID: 25817799OAI: oai:DiVA.org:liu-119236DiVA: diva2:821266
Note

Funding Agencies|Emil Andersson Research Fund

Available from: 2015-06-15 Created: 2015-06-12 Last updated: 2016-04-24

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Dreimane, Arta
By organisation
Department of HaematologyDepartment of Medical and Health SciencesFaculty of Medicine and Health Sciences
In the same journal
British Journal of Haematology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 65 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf